Efficacy and safety of venlafaxine-ECT combination in treatment-resistant depression

J Neuropsychiatry Clin Neurosci. 2002 Spring;14(2):206-9. doi: 10.1176/jnp.14.2.206.

Abstract

Thirteen patients with treatment-resistant major depression were given venlafaxine, at doses ranging from 150 mg to 375 mg, combined with ECT. Propofol was used as an anesthetic. Ten of 13 (76.9%) were considered responsive to combined ECT-venlafaxine treatment, and positive responses were not associated with venlafaxine doses. An asystole episode was observed in 4 patients; these patients had received significantly higher doses of venlafaxine (P<0.01). Treatment seems to be safe at venlafaxine doses <300 mg/day. At higher doses, with propofol used as anesthetic, the possibility of asystole cannot be ruled out. A possible additive effect of high-dose venlafaxine and propofol-blocking sodium channels are discussed.

MeSH terms

  • Aged
  • Anesthetics, Intravenous / pharmacology
  • Anesthetics, Intravenous / therapeutic use
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Cyclohexanols / administration & dosage
  • Cyclohexanols / adverse effects
  • Cyclohexanols / therapeutic use*
  • Depressive Disorder, Major / drug therapy
  • Depressive Disorder, Major / therapy*
  • Drug Administration Schedule
  • Electroconvulsive Therapy / methods*
  • Female
  • Heart Arrest / chemically induced
  • Heart Arrest / drug therapy
  • Heart Arrest / epidemiology
  • Heart Rate / drug effects
  • Humans
  • Male
  • Middle Aged
  • Propofol / pharmacology
  • Propofol / therapeutic use
  • Retrospective Studies
  • Sodium Channels / drug effects
  • Venlafaxine Hydrochloride

Substances

  • Anesthetics, Intravenous
  • Antidepressive Agents, Second-Generation
  • Cyclohexanols
  • Sodium Channels
  • Venlafaxine Hydrochloride
  • Propofol